Project Grant R44CA295425
Award Date
8/15/24
Completion Date
7/31/26
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award of $635,754 from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program will support the development of next-generation proteomics technologies to transform kinome research at the University of Massachusetts Medical School. The key objectives are to: 1) create a targeted kinome assay for simultaneous absolute and relative quantification of the full human kinome, 2) develop a high-throughput kinome-focused compound library screening platform, and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program award provides $274,990 to Dencoda LLC to develop a novel DNA-based kinase assay platform. The key products to be delivered are: A highly sensitive, specific, and multiplexed kinase activity assay that can be used as a research tool to discover new therapeutic targets or as a clinical diagnostic test for diseases involving kinase dysregulation, such as cancers, diabetes, and Alzheimer's disease....
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $391,531 to Yale University to develop technology for directing phosphorylation of specific protein kinase substrates. The goal is to engineer a kinase mutant that can selectively phosphorylate a designer allele of one of its substrates, using knowledge of kinase phosphorylation site specificity. The researchers will establish the feasibility of this approach using the tumor...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under CFDA 93.859 Biomedical Research and Research Training program, provides $345,285 to Kasa Bio, L.L.C., a woman-owned small business located in Norcross, Georgia, to develop a higher order multiplex technology to expand the capacity of digital PCR (dPCR) systems. The goal is to create a simple, probe-based multiplex dPCR method that can detect and quantify important gene fusions, such as BCR-ABL1...
This $440,287 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) is funding the development of a simplified, accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. The goal is to democratize cancer biobanking by enabling lower-resource institutes to conduct comprehensive molecular analyses on smaller tumor samples, including genomic sequencing, gene expression profiling, and protein...
This $109,906 Project Grant award from the National Cancer Institute's (NCI) Cancer Research Manpower program (CFDA 93.398) supports the development and application of novel RAS protein activity sensors and tools to uncover the mechanisms driving resistance to RAS inhibitor cancer drugs. The project aims to: (1) develop and apply RAS sensors in complex cancer cell models, (2) design RAS isoform-selective tools, and (3) profile and dissect the mechanisms underlying RAS inhibitor resistance. The...
The federal Project Grant award R33CA291166 was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The $419,133 grant supports the development of the "AscitesPredict" technology, which is a novel "ex vivo tumor biosensor" system that uses single-cell analysis and machine learning to evaluate cell identities and therapeutic sensitivities in cancer patient ascites samples. The goals of the 3-year project...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $273,388 to Histone Therapeutics, a woman-owned small business, aims to epigenetically modify natural killer (NK) cells to enhance their ability to detect and kill cancer cells. The goal is to develop a broad-spectrum NK cell therapy that can be used in combination with current cancer treatments to improve effectiveness without increasing side effects. The project will assess...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...